	2012 Mar 31	2013 Mar 31	2014 Mar 31	R 2015 Mar 31	2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Total Revenue	342	452	558	660	791	912	1,057	1,203	1,330	1,581	2,087	2,017	2,227	2,461	2,763
Cost of Operating Revenue	96	118	145	179	214	238	274	316	388	493	632	623	621	650	724
Gross Profit	246	334	413	481	577	674	783	887	942	1,088	1,455	1,394	1,606	1,811	2,039
Gross Margin	71.9	73.9	74.0	72.9	73.0	73.9	74.0	73.7	70.8	68.8	69.7	69.1	72.1	73.6	73.8
Total Operating Expenses	275	374	445	532	610	702	826	948	1,060	1,222	1,633	1,677	1,761	1,906	2,141
Operating Profit	67	78	113	128	181	210	231	255	271	359	455	340	466	556	622
Operating Margin	19.5	17.2	20.2	19.4	22.9	23.0	21.9	21.2	20.4	22.7	21.8	16.8	20.9	22.6	22.5
Financing Income/(Expense) - Net	-1	2	6	11	18	26	29	40	30	28	17	-4	26	41	52
Profit before Taxes	66	80	119	140	201	237	261	301	311	394	475	344	505	625	669
Income Taxes	21	25	39	43	67	81	90	100	83	98	125	103	143	133	159
Profit after Tax	45	55	80	96	132	155	171	199	226	292	345	239	358	487	505
PAT Margin	13.1	12.2	14.3	14.5	16.7	16.9	16.2	16.6	17.0	18.4	16.5	11.8	16.1	19.8	18.3
EPS - Basic - ex Extraordinary Items	2.71	3.34	4.82	8.40	8.05	9.51	10.42	12.10	13.71	17.66	20.85	14.41	21.52	29.24	30.24
EPS - Diluted - ex Extraordinary Items	2.71	3.34	4.82	5.83	7.99	9.48	10.41	12.07	13.68	17.62	20.79	14.37	21.49	29.20	30.20
EBIT	67	78	113	128	181	210	231	255	271	359	455	340	466	556	622
EBITDA	87	98	140	156	210	238	264	294	344	436	563	490	609	697	784
EBITDA Margin	25.3	21.7	25.1	23.7	26.5	26.1	25.0	24.4	25.8	27.6	27.0	24.3	27.4	28.3	28.4

Balance Sheet

Abridged

Understanding Balance Sheet

Dr. Lal Pathlabs Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	C 2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	PR	PR	PR	PR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	42	117	170	282	365	467	623	814	893	1,145	875	973	1,127	1,364	1,566
Long-Term Investments	1	2	0	0	-	-	-	-	-	-	-	-	34	33	33
Property Plant & Equipment - Net	71	76	77	92	106	124	169	164	302	312	430	404	347	339	489
Total Non-Current Assets	135	152	181	194	186	224	293	277	482	516	1,472	1,412	1,329	1,353	1,580
Total Assets	177	269	352	475	551	690	916	1,091	1,374	1,661	2,347	2,386	2,456	2,717	3,146
Total Current Liabilities	49	89	97	112	76	85	116	138	227	274	500	470	464	402	451
Long Term Debt	-	-	-	-	-	-	-	-	93	110	306	213	103	103	145
Total Non-Current Liabilities	11	16	21	20	5	7	8	1	93	111	310	216	107	108	154
Total Liabilities	60	105	118	132	82	92	124	140	320	385	810	686	571	510	605
Total Shareholders' Equity	116	162	231	341	467	596	788	945	1,033	1,245	1,502	1,666	1,849	2,173	2,508
Minority Interest	1	2	2	2	3	2	4	5	21	31	35	33	36	34	33
Total Equity	117	164	233	343	470	598	792	951	1,054	1,276	1,537	1,700	1,885	2,206	2,541
Total Liabilities & Equity	177	269	352	475	551	690	916	1,091	1,374	1,661	2,347	2,386	2,456	2,717	3,146

Cash Flow

Abridged

Understanding Cash Flow Statement

Dr. Lal Pathlabs Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	C 2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	67	94	111	140	155	203	215	236	312	385	483	413	516	604	653
Working Capital - Increase/(Decrease)	0	-3	-9	-8	19	-8	10	9	12	37	-17	35	36	6	27
Net CF from Operating Activities	67	91	102	132	174	195	224	245	325	422	466	449	551	610	679
Capital Expenditures - Net	21	19	32	35	43	51	72	42	79	59	474	44	57	53	173
Net CF from Investing Activities	-28	-68	-94	-124	-180	-161	-199	-127	-67	-252	-499	-318	-70	-366	-488
Dividends Paid - Cash - Total	-	-	-	10	16	37	32	55	156	99	117	103	201	207	223
Stock - Issuance/(Retirement) - Net	-7	0	-	11	17	4	44	0	0	0	0	1	3	13	19
Debt - LT & ST - Issuance/(Retirement) - Total	-20	0	-	-1	-	-	-	-	-35	-24	283	-143	-187	-117	-37
Net Cash Flow from Financing Activities	-36	-15	-10	-1	1	-32	13	-55	-190	-123	167	-245	-385	-312	-241
Free Cash Flow to Equity	27	72	69	96	131	144	152	203	211	339	275	262	308	439	470
Free Operating CF net dividend	46	71	69	87	114	106	120	148	90	263	-127	301	293	349	283
Free Operating CF	46	71	69	97	130	143	152	203	245	362	-10	404	494	556	506

Business Segment Analysis

FY End:

Mar 26

Dr. Lal Pathlabs Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Laboratories for pathological investigations (100.0%)₹ 173.38 Cr

Revenue / Sales

Laboratories for pathological investigations (100.0%)₹ 2,762.91 Cr

Assets

Laboratories for pathological investigations (100.0%)₹ 3,146.00 Cr

Operating Income

Laboratories for pathological investigations (100.0%)₹ 622.33 Cr

Regional Segment Analysis

FY End:

Mar 26

Dr. Lal Pathlabs Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (99.2%)₹ 2,741.47 CrOutside India (0.8%)₹ 21.45 Cr

Historical Segment Analysis

Track how Dr. Lal Pathlabs Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Laboratories for pathological investigations	80	60	476	45	57	54	173

Frequently Asked Questions

What is the revenue of Dr. Lal Pathlabs Ltd.?

The latest trailing twelve month revenue of Dr. Lal Pathlabs Ltd. is ₹ 2,762.90 Cr, reflecting a 1-year growth of 12.25% and a 3-year CAGR of 11.06%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Dr. Lal Pathlabs Ltd.?

The latest trailing twelve month net profit (PAT) of Dr. Lal Pathlabs Ltd. is ₹ 504.80 Cr, with a 3-year earnings CAGR of 28.10%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Dr. Lal Pathlabs Ltd.?

The trailing twelve month EBITDA of Dr. Lal Pathlabs Ltd. is approximately ₹ 620.70 Cr (based on an operating margin of 22.47%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Dr. Lal Pathlabs Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Dr. Lal Pathlabs Ltd. is 30.20. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Dr. Lal Pathlabs Ltd.?

The debt-to-equity ratio of Dr. Lal Pathlabs Ltd. stands at 0.08. The interest coverage ratio is 27.22x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Dr. Lal Pathlabs Ltd.?

The estimated book value per share of Dr. Lal Pathlabs Ltd. is 149.33 (derived from a P/B ratio of 10.98 and market price of ₹ 1,639.10), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Dr. Lal Pathlabs Ltd.?

The trailing twelve month operating cash flow of Dr. Lal Pathlabs Ltd. is ₹ 679.30 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Dr. Lal Pathlabs Ltd. report consolidated or standalone financials?

Dr. Lal Pathlabs Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.